PrintFriendly
Medical News
|
Wednesday, September 1, 2010 Baxter Healthcare Corporation made a public announcement in August that it is updating certain sections of the prescribing information for FEIBA VH® and FEIBA NF®after consistent reports of thrombosis (excessive clots forming in blood vessels) and thromboembolic events associated with the use of the products, particularly in high doses or in at-risk patients. |
|
Wednesday, September 1, 2010 In July, investigators from The Children’s Hospital of Philadelphia (CHOP) published a review of their research into the molecular processes that ensure factors V (FV) and VIII (FVIII) become “activated” to carry out their role as coagulation proteins. These and other proteins function in the “clotting cascade,” an intricate series of chemical and molecular reactions between clotting factors that lead to clot formation. |
|
Wednesday, September 1, 2010 In a study published in the August Journal of Pediatric and Adolescent Gynecology, researchers from the Royal Free Hospital (RFH) in London reviewed the management and treatment outcomes in adolescents with inherited bleeding disorders and menorrhagia (excessive menstrual bleeding). |
|
Friday, October 1, 2010 In September, investigators from the Yale School of Medicine (YSM) revealed the discovery of a new animal model for future hemophilia A research—lab rats. |
|
Friday, October 1, 2010 In an August review article, physicians from the Tulane University School of Medicine (TUSM) outlined some of the challenges and treatment options for emergency room (ER) staff when dealing with patients with bleeding disorders. |
|
Friday, October 1, 2010 “The Jewelry Prescription: Medical Bracelets Go High Tech,” an article in the Wall Street Journal on August 31, 2010, highlighted the importance of carrying or wearing a form of medical identification (ID), particularly for individuals with complex and/or chronic medical conditions and/or food or drug allergies. It featured recent advances in personal medical identification. |
|
Monday, November 1, 2010 Using genetically modified plants, researchers from two Florida universities are developing a technique that could help prevent treatment-related complications such as inhibitors, an immune reaction that neutralizes infused factor, and anaphylaxis, severe allergic reactions, in people with hemophilia B. |
|
Monday, November 1, 2010 A study published in October suggests that oral tranexamic acid (TA) may have two benefits: reducing heavy menstrual bleeding (menorrhagia) in women and improving their quality of life. |
|
Tuesday, June 1, 2010 On April 30, 2010, physicians and patients provided public testimony to the Food and Drug Administration (FDA) in favor of allowing seriously ill people with hepatitis C ( |
|
In an April 2010 study, researchers at the Mayo Clinic examined health-related quality of life (HRQoL) and satisfaction of women with bleeding disorders who had undergone global endometrial ablation (GEA) for excessive menstrual bleeding. |